肝脏超声造影成像:SonoVue与Sonazoid临床证据综述
本文综述并比较了SonoVue(纯血池造影剂)与Sonazoid(具有额外Kupffer期)两种超声造影剂在非肝硬化和肝硬化肝脏局灶性病变定性、检测以及介入操作(如肝活检引导和局部消融治疗监测)中的当前临床证据,引用了以参考标准评估CEUS准确性、安全性或比较两种造影剂的研究。
要点
- SonoVue为纯血池造影剂,Sonazoid具有额外Kupffer期,两者均获批用于肝脏成像。
- 综述比较了两者在非肝硬化和肝硬化肝脏局灶性病变定性及检测中的临床证据。
- 综述涵盖肝活检引导和局部消融治疗监测等介入应用中的CEUS证据。
核心结论
- 本文讨论并比较了SonoVue与Sonazoid在肝脏局灶性病变定性和检测以及介入操作中的当前临床证据。
研究设计与样本
- 综述类文章,引用了以参考标准评估CEUS准确性或安全性的临床研究以及两种造影剂的比较研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Contrast-enhanced ultrasound (CEUS) has become an established modality in various clinical indications for liver diseases. SonoVue®, a pure blood pure agent, and Sonazoid®, which exhibits an additional Kupffer phase, are contrast agents approved for liver imaging. This review discusses and compares the current clinical evidence for these two ultrasound contrast agents in the characterization and detection of focal liver lesions in the non-cirrhotic and cirrhotic liver, as well as for the use in interventional procedures such as liver biopsy guidance, and local ablation treatment monitoring. Reference is made to clinical studies which evaluated the accuracy of CEUS using a standard of reference, its safety, or to comparative studies of these two agents.
引用
- Barr RG, Huang P, Luo Y, et al. Contrast-enhanced ultrasound imaging of the liver: a review of the clinical evidence for SonoVue and Sonazoid. Abdom Radiol (NY). 2020. PMID: 32424608. doi:10.1007/s00261-020-02573-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。